333 related articles for article (PubMed ID: 35205769)
41. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
42. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
43. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
44. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
45. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
Kung PJ; Lai TY; Cao J; Hsu LC; Chiang TC; Ou-Yang P; Tsai CY; Tsai YF; Lin CW; Chen CC; Tsai MK; Tien YW; Lee CY
Cancer Immunol Immunother; 2022 Mar; 71(3):705-718. PubMed ID: 34374812
[TBL] [Abstract][Full Text] [Related]
46. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
[TBL] [Abstract][Full Text] [Related]
47. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing.
Yao J; Shi Y; Cao K; Lu L; Lu J; Song Q; Jin G; Xiao J; Hou Y; Zhang L
Med Image Anal; 2021 Oct; 73():102150. PubMed ID: 34303891
[TBL] [Abstract][Full Text] [Related]
48. KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8.
Li B; Liu B; Zhang X; Liu H; He L
J Cell Physiol; 2020 May; 235(5):4227-4238. PubMed ID: 31875977
[TBL] [Abstract][Full Text] [Related]
49. Gender-specific changes of the gut microbiome correlate with tumor development in murine models of pancreatic cancer.
Kaune T; Griesmann H; Theuerkorn K; Hämmerle M; Laumen H; Krug S; Plumeier I; Kahl S; Junca H; Gustavo Dos Anjos Borges L; Michl P; Pieper DH; Rosendahl J
iScience; 2023 Jun; 26(6):106841. PubMed ID: 37255660
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.
Wang Y; Zhong X; Zhou L; Lu J; Jiang B; Liu C; Guo J
Front Oncol; 2020; 10():1466. PubMed ID: 33042793
[No Abstract] [Full Text] [Related]
51. [Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma].
Zhou L; Sheng WW; Shi XY; Zhou JP; Dong M
Zhonghua Wai Ke Za Zhi; 2019 Mar; 57(3):206-211. PubMed ID: 30861650
[No Abstract] [Full Text] [Related]
52. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
53. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
54. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
Oron Y
Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
[TBL] [Abstract][Full Text] [Related]
55. Pancreatic Ductal Adenocarcinoma: Current and Emerging Therapeutic Uses of Focused Ultrasound.
Lafond M; Lambin T; Drainville RA; Dupré A; Pioche M; Melodelima D; Lafon C
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681557
[TBL] [Abstract][Full Text] [Related]
56. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma.
Gong Y; Fan Z; Luo G; Huang Q; Qian Y; Cheng H; Jin K; Ni Q; Yu X; Liu C
Pancreatology; 2020 Jun; 20(4):716-721. PubMed ID: 32249060
[TBL] [Abstract][Full Text] [Related]
57. Proteomic analysis of pancreatic ductal adenocarcinoma.
Meleady P; Abdul Rahman R; Henry M; Moriarty M; Clynes M
Expert Rev Proteomics; 2020 Jun; 17(6):453-467. PubMed ID: 32755290
[TBL] [Abstract][Full Text] [Related]
58. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
59. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
[TBL] [Abstract][Full Text] [Related]
60. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.
Atay S
PeerJ; 2020; 8():e10141. PubMed ID: 33194391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
